Intelligent SkinCare Intensive Brightening

Belo Intensive Brightening by

Drug Labeling and Warnings

Belo Intensive Brightening by is a Otc medication manufactured, distributed, or labeled by Intelligent Skin Care Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

BELO INTENSIVE BRIGHTENING- octyl methoxycinnamate, titanium dioxide, octocrylene, octinoxate lotion 
Intelligent Skin Care Inc.

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

----------

Intelligent SkinCare Intensive Brightening

Active Ingredients

Active Ingredients Purpose

Octyl methoxycinnamate 6% Sunscreen

Octocrylene .60%

Oxybenzone .50%

Titanium dioxide .41%

Purpose

Purpose

Sunscreen

Use

Use

helps prevent sunburn

Warnings

Skin Cancer/Skin Aging Alert: Spending time in the sun increases your risk of skin cancer and early skin aging. This product has been shown only to help prevent sunburn, not skin cancer or early skin aging.

For external use only

Do not use on damaged or broken skin

When using this product keep out of eyes. Rinse with water to remove.

Stop use and ask a doctor if rash occurs.

Keep out of reach of children. If product is swallowed, get Poison Control Center right away.

Directions

  • apply liberally 15 minutes before sun exposure.
  • reapply at least every 2 hours.
  • use a water-resistant sunscreen if swimming or sweating.
  • children under 6 months of age: Ask a doctor.

Other Information

Other Information

protect the product in this container from excessive heat and direct sun

  • high sun protection product

Inactive Ingredients

Inactive Ingredientsinactive

Questions or Comments?

Questions or Comments?

+63 2 7500 3825 or inquiries@iskincareinc.com

label

label

BELO INTENSIVE BRIGHTENING 
octyl methoxycinnamate, titanium dioxide, octocrylene, octinoxate lotion
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC: 82701-003
Route of AdministrationTOPICAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
OXYBENZONE (UNII: 95OOS7VE0Y) (OXYBENZONE - UNII:95OOS7VE0Y) OXYBENZONE1 mg  in 200 mg
TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE0.82 mg  in 200 mg
OCTOCRYLENE (UNII: 5A68WGF6WM) (OCTOCRYLENE - UNII:5A68WGF6WM) OCTOCRYLENE1.2 mg  in 200 mg
OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE12 mg  in 200 mg
Inactive Ingredients
Ingredient NameStrength
CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE (UNII: 0A5MM307FC)  
BUTYROSPERMUM PARKII (SHEA) BUTTER UNSAPONIFIABLES (UNII: 0C9AC7D6XU)  
LEVOMENOL (UNII: 24WE03BX2T)  
CETOSTEARYL ALCOHOL (UNII: 2DMT128M1S)  
DIMETHICONE (UNII: 92RU3N3Y1O)  
BUTYLENE GLYCOL (UNII: 3XUS85K0RA)  
ETHYLHEXYL METHOXYCRYLENE (UNII: S3KFG6Q5X8)  
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
AVOBENZONE (UNII: G63QQF2NOX)  
CETEARETH-12 (UNII: 7V4MR24V5P)  
CETYL PALMITATE (UNII: 5ZA2S6B08X)  
GLYCERYL MONOSTEARATE (UNII: 230OU9XXE4)  
SORBITAN OLIVATE (UNII: MDL271E3GR)  
EDETATE SODIUM (UNII: MP1J8420LU)  
PEG-80 SORBITAN PALMITATE (UNII: 4NR71FN0IA)  
CYCLOMETHICONE 4 (UNII: CZ227117JE)  
POLYOXYL 20 CETOSTEARYL ETHER (UNII: YRC528SWUY)  
NIACINAMIDE (UNII: 25X51I8RD4)  
WATER (UNII: 059QF0KO0R)  
CYCLOMETHICONE 5 (UNII: 0THT5PCI0R)  
CETYL ALCOHOL (UNII: 936JST6JCN)  
ETHYLHEXYLGLYCERIN (UNII: 147D247K3P)  
ALUMINUM OXIDE (UNII: LMI26O6933)  
ALKYL (C12-15) BENZOATE (UNII: A9EJ3J61HQ)  
KOJIC ACID (UNII: 6K23F1TT52)  
PHENOXYETHANOL (UNII: HIE492ZZ3T)  
TROLAMINE (UNII: 9O3K93S3TK)  
GLUCONOLACTONE (UNII: WQ29KQ9POT)  
TRANEXAMIC ACID (UNII: 6T84R30KC1)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC: 82701-003-01200 mg in 1 TUBE; Type 0: Not a Combination Product06/20/2022
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC monograph finalM02006/20/2022
Labeler - Intelligent Skin Care Inc. (719667461)

Revised: 11/2022